<VariationArchive VariationID="2574178" VariationName="NC_000019.9:g.(?_11240188)_(11240347_?)del" VariationType="Deletion" Accession="VCV002574178" Version="1" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-23" DateCreated="2023-08-06" MostRecentSubmission="2023-08-05">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="2739113" VariationID="2574178">
      <GeneList>
        <Gene Symbol="LDLR" FullName="low density lipoprotein receptor" GeneID="3949" HGNC_ID="HGNC:6547" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>19p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="11089463" stop="11133820" display_start="11089463" display_stop="11133820" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="11200037" stop="11244505" display_start="11200037" display_stop="11244505" Strand="+" />
          </Location>
          <OMIM>606945</OMIM>
          <Haploinsufficiency last_evaluated="2021-10-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LDLR">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-10-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LDLR">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000019.9:g.(?_11240188)_(11240347_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>19p13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" innerStart="11240188" innerStop="11240347" display_start="11240188" display_stop="11240347" variantLength="160" />
      </Location>
      <OtherNameList>
        <Name>NM_000527.4(LDLR):c.2390-?_2547+?del</Name>
      </OtherNameList>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.(?_11240188)_(11240347_?)del" Assembly="GRCh37">
            <Expression>NC_000019.9:g.(?_11240188)_(11240347_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000019.9:g.(?_11240188)_(11240347_?)del AND Hypercholesterolemia, familial, 1" Accession="RCV003318760" Version="2">
        <ClassifiedConditionList TraitSetID="7435">
          <ClassifiedCondition DB="MedGen" ID="C0745103">Hypercholesterolemia, familial, 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>reviewed by expert panel</ReviewStatus>
            <Description DateLastEvaluated="2023-04-28" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-04-28" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2023-08-06" MostRecentSubmission="2023-08-05">
        <ReviewStatus>reviewed by expert panel</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/4cdf29f1-f197-4328-8ef1-0a95ae6e5b6c</URL>
        </Citation>
        <ConditionList>
          <TraitSet ID="7435" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="15983" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Hypercholesterolemia, familial, 1</ElementValue>
                <XRef ID="MONDO:0007750" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">LDL RECEPTOR DISORDER</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperlipoproteinemia Type IIa</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">HYPER-LOW-DENSITY-LIPOPROTEINEMIA</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">HYPERCHOLESTEROLEMIC XANTHOMATOSIS, FAMILIAL</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
                <XRef Type="MIM" ID="144400" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Fredrickson type IIa hyperlipoproteinemia</ElementValue>
                <XRef ID="397915002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperlipoproteinemia type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyper-beta-lipoproteinemia</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyperlipoproteinemia Type II</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">HYPERCHOLESTEROLEMIA, FAMILIAL, MODIFIER OF</ElementValue>
                <XRef Type="Allelic variant" ID="600946.0028" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FHC</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">FH</ElementValue>
                <XRef Type="MIM" ID="143890" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Familial hypercholesterolemia (FH) is characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) that leads to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age and increases the risk of premature cardiovascular events such as angina and myocardial infarction; stroke occurs more rarely. Xanthomas (cholesterol deposits in tendons) may be visible in the Achilles tendons or tendons of the hands and worsen with age as a result of extremely high cholesterol levels. Xanthelasmas (yellowish, waxy deposits) can occur around the eyelids. Individuals with FH may develop corneal arcus (white, gray, or blue opaque ring in the corneal margin as a result of cholesterol deposition) at a younger age than those without FH. Individuals with a more severe phenotype, often as a result of biallelic variants, can present with very significant elevations in LDL-C (&gt;500 mg/dL), early-onset coronary artery disease (CAD; presenting as early as childhood in some), and calcific aortic valve disease.</Attribute>
                <XRef ID="NBK174884" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="NICE, 2019">
                <URL>https://www.nice.org.uk/guidance/CG71</URL>
                <CitationText>National Institute for Health and Clinical Excellence, Identification and management of familial hypercholesterolaemia, 2008 [Updated: 4 October 2019]</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="general" Abbrev="CSANZ, 2012">
                <ID Source="PubMed">22364837</ID>
              </Citation>
              <Citation Type="general" Abbrev="IPMFH, 2004">
                <ID Source="PubMed">15177124</ID>
              </Citation>
              <Citation Type="general" Abbrev="NLAEP, 2011">
                <ID Source="PubMed">21600525</ID>
              </Citation>
              <Citation Type="general" Abbrev="Int'l FH Foundation, 2014">
                <ID Source="PubMed">24418289</ID>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24404629</ID>
                <ID Source="BookShelf">NBK174884</ID>
              </Citation>
              <Citation Type="general" Abbrev="Feldman et al., 2015">
                <ID Source="PubMed">25404096</ID>
              </Citation>
              <Citation Type="general" Abbrev="EAS, 2014">
                <ID Source="PubMed">25053660</ID>
              </Citation>
              <Citation Type="general" Abbrev="PLEF, 2014">
                <ID Source="PubMed">24636176</ID>
              </Citation>
              <Citation Type="general" Abbrev="PLEF, 2013">
                <ID Source="PubMed">23725921</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="Position Statement" Abbrev="CSANZ, 2016">
                <URL>https://www.csanz.edu.au/wp-content/uploads/2017/07/Familial-Hypercholesterolaemia_ratified_-25-Nov-2016.pdf</URL>
                <CitationText>The Cardiac Society of Australia and New Zealand, Diagnosis and Management of Familial Hypercholesterolaemia – Position Statement</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2019">
                <URL>https://www.acmg.net/PDFLibrary/Familial-Hypercholesterolemia.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Genomic Testing (Secondary Findings) ACT Sheet, APOB, LDLR, PCSK9 Pathogenic Variants (Familial Hypercholesterolemia), 2019</CitationText>
              </Citation>
              <XRef ID="391665" DB="Orphanet" />
              <XRef ID="C0745103" DB="MedGen" />
              <XRef ID="MONDO:0007750" DB="MONDO" />
              <XRef Type="MIM" ID="143890" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion FDARecognizedDatabase="true" ID="7526047" SubmissionDate="2023-07-28" DateLastUpdated="2023-08-05" DateCreated="2023-08-05">
        <ClinVarSubmissionID localKey="4cdf29f1-f197-4328-8ef1-0a95ae6e5b6c" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV004022463" DateUpdated="2023-08-05" DateCreated="2023-08-05" Type="SCV" Version="1" SubmitterName="ClinGen Familial Hypercholesterolemia Variant Curation Expert Panel" OrgID="508055" OrganizationCategory="consortium" OrgAbbreviation="ClinGen FH VCEP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-04-28">
          <ReviewStatus>reviewed by expert panel</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/4cdf29f1-f197-4328-8ef1-0a95ae6e5b6c</URL>
          </Citation>
          <Comment>The NM_000527.5(LDLR):c.2390-?_2547+?del variant is classified as Pathogenic for Familial Hypercholesterolemia by applying evidence codes (PVS1, PM2, PS4_moderate, PP1 and PP4) as defined by the ClinGen Familial Hypercholesterolemia Expert Panel LDLR-specific variant curation guidelines (https://doi.org/10.1016/j.gim.2021.09.012). The supporting evidence is as follows: PVS1 - Variant is deletion of exon 17 predicted to lead to out-of frame consequence. PM2 - This variant is absent from gnomAD (gnomAD SVs v2.1). PS4_moderate - Variant meets PM2 and is identified in 6 unrelated index cases (1 case with DLCN criteria&gt;=6 from PMID: 2837085 (Langlois et al., 1988), Canada.; 1 case with Simon-Broome criteria of possible FH from PMID: 19538517 (Taylor et al., 2009), United Kingdom ; 1 case with Simon-Broome criteria of definitive FH from PMID: 1863993 (Rüdiger et al., 1991), Denmark; 2 index cases with DLCN criteria&gt;=6 from Centre de Genetique Moleculaire et Chromosomique, Unite de genetique de l'Obesite et des Dyslipidemies (APHP, Sorbonne Universite, Hopitalde la Pitie-Salpetriere), France; 1 index case with DLCN criteria&gt;=6 from Cardiovascular Genetics Laboratory (PathWest Laboratory Medicine), Australia. PP1 - Variant segregates with FH phenotype in 3 informative meiosis in 2 families from different sources (PMID: 1863993 (Rüdiger et al., 1991), Denmark: Centre de Genetique Moleculaire et Chromosomique, Unite de genetique de l'Obesite et des Dyslipidemies (APHP, Sorbonne Universite, Hopitalde la Pitie-Salpetriere), France): 3 affected family members have the variant. PP4 - Variant meets PM2 and is identified in at least one case who fufills clinical criteria for FH (see PS4 for details), after alternative causes of high cholesterol were excluded.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Semidominant inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">ClinGen FH ACMG Specifications v1-2</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/api/2.0/files/mg2eil60/clingen_fh_acmg_specifications_v1-2.pdf/?format=attachment</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="LDLR" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_000527.4(LDLR):c.2390-?_2547+?del</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.(?_11240188)_(11240347_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0007750" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13716206</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="7526047" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0007750" MappingRef="MONDO">
        <MedGen CUI="C0745103" Name="Hypercholesterolemia, familial, 1" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

